Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.24
CORT's Cash to Debt is ranked higher than
58% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CORT: 1.24 )
CORT' s 10-Year Cash to Debt Range
Min: 1.24   Max: No Debt
Current: 1.24

Equity to Asset 0.18
CORT's Equity to Asset is ranked higher than
50% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CORT: 0.18 )
CORT' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.89
Current: 0.18

0.18
0.89
F-Score: 3
Z-Score: -7.14
M-Score: -2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -400.66
CORT's Operating margin (%) is ranked higher than
61% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CORT: -400.66 )
CORT' s 10-Year Operating margin (%) Range
Min: -69827.59   Max: -400.66
Current: -400.66

-69827.59
-400.66
Net-margin (%) -444.25
CORT's Net-margin (%) is ranked higher than
59% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CORT: -444.25 )
CORT' s 10-Year Net-margin (%) Range
Min: -69537.93   Max: -444.25
Current: -444.25

-69537.93
-444.25
ROE (%) -218.92
CORT's ROE (%) is ranked higher than
50% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. CORT: -218.92 )
CORT' s 10-Year ROE (%) Range
Min: -391.08   Max: -33.31
Current: -218.92

-391.08
-33.31
ROA (%) -72.94
CORT's ROA (%) is ranked higher than
57% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CORT: -72.94 )
CORT' s 10-Year ROA (%) Range
Min: -251.19   Max: -30.73
Current: -72.94

-251.19
-30.73
ROC (Joel Greenblatt) (%) -20441.38
CORT's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. CORT: -20441.38 )
CORT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -685925   Max: -20441.38
Current: -20441.38

-685925
-20441.38
EBITDA Growth (%) 2.60
CORT's EBITDA Growth (%) is ranked higher than
83% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CORT: 2.60 )
CORT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 2.6
Current: 2.6

0
2.6
EPS Growth (%) 6.60
CORT's EPS Growth (%) is ranked higher than
85% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. CORT: 6.60 )
CORT' s 10-Year EPS Growth (%) Range
Min: -31.3   Max: 6.6
Current: 6.6

-31.3
6.6
» CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CORT Guru Trades in Q2 2013

Steven Cohen 450,000 sh (New)
Jean-Marie Eveillard 2,536,866 sh (unchged)
» More
Q3 2013

CORT Guru Trades in Q3 2013

Steven Cohen 500,000 sh (+11.11%)
Jean-Marie Eveillard 2,496,078 sh (-1.61%)
» More
Q4 2013

CORT Guru Trades in Q4 2013

Steven Cohen Sold Out
Jean-Marie Eveillard 991,978 sh (-60.26%)
» More
Q1 2014

CORT Guru Trades in Q1 2014

Steven Cohen 14,329 sh (New)
Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out 0.01%$2.8 - $4.12 $ 2.47-29%0
Jean-Marie Eveillard 2013-12-31 Reduce -60.26%0.01%$1.6 - $3.17 $ 2.4723%991978
Jean-Marie Eveillard 2012-12-31 Add 104.3%0.01%$1.29 - $2.75 $ 2.4730%2536866
Jean-Marie Eveillard 2012-09-30 Add 25.21%$2.58 - $4.49 $ 2.47-28%1241766
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 27.50
CORT's P/B is ranked higher than
56% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. CORT: 27.50 )
CORT' s 10-Year P/B Range
Min: 0.78   Max: 45.78
Current: 27.5

0.78
45.78
P/S 19.00
CORT's P/S is ranked higher than
72% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. CORT: 19.00 )
CORT' s 10-Year P/S Range
Min: 14.15   Max: 615
Current: 19

14.15
615
EV-to-EBIT -5.24
CORT's EV-to-EBIT is ranked higher than
73% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CORT: -5.24 )
CORT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -5.24

Current Ratio 3.16
CORT's Current Ratio is ranked higher than
69% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CORT: 3.16 )
CORT' s 10-Year Current Ratio Range
Min: 2.22   Max: 37.77
Current: 3.16

2.22
37.77
Quick Ratio 3.08
CORT's Quick Ratio is ranked higher than
70% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CORT: 3.08 )
CORT' s 10-Year Quick Ratio Range
Min: 2.22   Max: 37.77
Current: 3.08

2.22
37.77

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 123.50
CORT's Price/Net Current Asset Value is ranked higher than
70% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. CORT: 123.50 )
CORT' s 10-Year Price/Net Current Asset Value Range
Min: 2.5   Max: 218
Current: 123.5

2.5
218
Price/Tangible Book 27.40
CORT's Price/Tangible Book is ranked higher than
60% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. CORT: 27.40 )
CORT' s 10-Year Price/Tangible Book Range
Min: 2.31   Max: 48.44
Current: 27.4

2.31
48.44
Price/Median PS Value 0.10
CORT's Price/Median PS Value is ranked higher than
99% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CORT: 0.10 )
CORT' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 2.36
Current: 0.1

0.09
2.36
Forward Rate of Return (Yacktman) -11.57
CORT's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. CORT: -11.57 )
CORT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 30   Max: 162.6
Current: -11.57

30
162.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HTD.Germany
Corcept Therapeutics, Inc. was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical Company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The Company's primarily focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym (mifepristone) 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.
» More Articles for CORT

Headlines

Articles On GuruFocus.com
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Jul 30 2014
Corcept Therapeutics to Announce Second Quarter Financial Results and Host Conference Call Jul 30 2014
Corcept Therapeutics to Announce Second Quarter Financial Results and Host Conference Call Jul 29 2014
/ CORRECTION - Corcept Therapeutics Jun 20 2014
New Research on Corcept's Korlym(R) for Patients With Cushing's Syndrome to Be Presented at ICE/ENDO... Jun 19 2014
Corcept Therapeutics: 4 Different Insiders Have Purchased Shares During The Last 30 Days Jun 03 2014
CORCEPT THERAPEUTICS INC Financials May 20 2014
Corcept Therapeutics Director Leonard Baker buys 100k shares on 5/9/14 May 12 2014
CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 12 2014
Corcept Therapeutics (CORT) in Focus: Stock Rises 5.8% May 12 2014
10 Russell 2000 stocks you're glad you never heard of May 09 2014
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 09 2014
Corcept Plunges on Study Results May 08 2014
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q1 2014 Results - Earnings Call Transcript May 07 2014
Why Corcept Therapeutics (CORT) Is Plummeting Today May 07 2014
Corcept shares slide 50% after it halts drug trial May 07 2014
Corcept Therapeutics stops depression drug trial May 07 2014
Corcept Therapeutics Announces First Quarter 2014 Financial Results May 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide